Vertex Pharmaceuticals is revealed to post results from the first phase III study of its experimental hepatitis C drug telaprevir sometime this quarter.

The first telaprevir data to be issued will come from the phase III study known as ADVANCE. The study is revealed to involve treatment-naïve hepatitis C patients.

In contrast to most phase III studies, investors assume 100% that telaprevir works and that the ADVANCE study will be positive.

At the stock index, Vertex share price registered is at a low $40s which basically bakes in a telaprevir cure rate of 70-75%, with citations that the stock will not witness a climb.

Telaprevir is revealed to be one of two highly anticipated drugs in the class known as protease inhibitors currently being studied in patients with chronic hepatitis C infection, a disease that engulfs about 3 million Americans and is the leading cause of liver transplants in the U. S.

The phase II study of Arqule's ARQ197 in second-line non-small cell lung cancer is definitely on the list.